 | |||
|
ECOG Introduction to ECOG Clinical Trials Guide For Cancer Patients What is a clinical trial? Why participate? Does insurance cover costs? What if I change my mind? How can I join a clinical trial? ECOG's active protocols Patient Information Selenium E5597 GI Studies E4203,E5202,E5204 Melanoma E2603 Prostate CHAARTED E3805 Cancer in Siblings E1Y97 Non-Hodgkins Lymphoma E4402 Breast Cancer PACCT1: TAILORx Informational Videos Trial Summary Results Trial Monitoring ECOG Data Monitoring Committee ECOG Institutions Institutions by state Alphabetical listing Joining ECOG Publications Publications bibliography Announcements TAILORx Webinar Information NCI Press Release: Bevacizumab... Job Openings Future ECOG Meeting Dates Researcher Advocate Partners Investigator Awards NCI-VA Initiative Scales and Criteria ECOG Performance Status Common Toxicity Criteria Cancer Information Breast Cancer Video Colon Cancer Video Cancer Survivor Publications Releasing Results Guidelines Other Cancer Sites ECOG Main Institutions' Sites Other Cooperative Groups Advocates/Support Groups 
ECOG MEMBERS
|
Eastern Cooperative Oncology Group:E1104 - Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Trastuzumab (Herceptin) in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer
Click here for a list of institutions participating in this trial Note to institutions: Use of these videos for patient education requires approval of your institution's IRB. Vorinostat and trastuzumab are monoclonal antibodies and may fight breast cancer by blocking the flow of blood to the tumor. Giving these two monoclonal antibodies together may be better at stopping the growth of tumor cells in HER2+ breast cancer than trastuzumab alone. It is not known whether trastuzumab plus vorinostat is more effective than trastuzumab alone in stopping the growth of tumor cells in HER2+ breast cancer. This phase II trial is studying how well these monocolonal antibodies will work in treating patients with metastatic HER2+ breast cancer or HER2+ breast cancer that has recurred in the chest wall. Patients will receive vorinostat by mouth twice a day for 2 weeks. They will also receive an infusion of trastuzumab in week 1. Treatment may repeat every 3 weeks for as long as benefit is shown. It is not known at this time whether there is any benefit that would result from the combination of tratuzumab and vorinostat in metastatic breast cancer or breast cancer that has recurred in the chest wall. This is the question that we hope will be answered by this trial. You can learn more about breast cancer treatment options by visiting these web sites:
Information about cancer clinical trials can be found at: |
You can learn more about this trial by viewing a short informational video featuring Dr. Ramona Swaby: